Sofosbuvir and Velpatasvir

Asegua Therapeutics LLC🇺🇸 United States

FDA Page

Effective Date: May 4, 2022
Approval ID: d0c1a945-4440-4b5c-81aa-693ed3db597c
Products: 1 registered
Version: 8

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use SOFOSBUVIR and VELPATASVIR TABLETS safely and effectively. See full prescribing information for SOFOSBUVIR and VELPATASVIR TABLETS. SOFOSBUVIR and VELPATASVIR tablets, for oral use, 400 mg/100 mg (Authorized generic of EPCLUSA) Initial U.S. Approval: 2016

Quick Stats

Total Products1

Labelers2

Label Sections20

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.